SPAC

The company said the deal could help it with commercialization and expansion. 

Valo’s flagship product is its Opal Computational Platform, designed to create a new model for drug discovery.   

The deal is expected to close in the second half of 2021 and be worth roughly $4.2 billion. 

Science 37 will have an initial enterprise value of approximately $1.05 billion.   

The prospect of companies hitting the public markets before they’re fully prepared creates the possibility for failure, according to Rock Health.  

The deal is expected to close this summer, subject to stockholder approval, and will raise $113 million for the combined company.   

Investment firm Kuwait Life Sciences Company's Dr. Mussaad M. Al-Razouki gives a breakdown of recently filed or finalized digital health SPACs, as well as a list of unicorns ripe for a potential merger.

The company currently sells connected wearables and smart monitors to consumers, but said that it will be seeking FDA authorization for new products with broader indications and telehealth capabilities down the line.

Also: docdok.health rolling out COVID-19 vaccination study app; IBM Watson Health partners with Humana.

Also: Study lends support to smartphone PPG pulse oximetry; Happify Health adds new language support to digitial mental health programs.